Screening urine for Chronic Kidney Disease – insights from Europe
Urinary Albumin Strip Assay as a Screening test to replace Quantitative technology
The clinical laboratory plays a crucial role in the diagnosis and monitoring of chronic kidney disease (CKD).
The quantitative measurement of urine albumin in a spot sample, expressed as ratio per creatinine (ACR), is the most frequently used biomarker for such purposes. This webinar will provide insights into the diagnostic performance of a strip for measuring ACR in order to differentiate patients who are candidates for subsequent albumin quantification. Savings in reagent can be used to design and implement interventions to improve the diagnosis of chronic kidney disease and the monitoring of patients with hypertension and type 2 diabetes.
Join us and discover possibilities for optimisation of the laboratory workflow, economic savings and clinical benefits in context of albuminuria screening.
Point-of-Care testing for Kidney disease – Lessons learnt from a resource-limited setting in South Africa
The prevalence of chronic kidney disease (CKD) is predicted to rise over the next few decades, with disproportionately high representation set to come from low and middle-income countries. In such settings, access to centralised laboratory services is often limited, hindering early detection and patient monitoring.
Point-of-care testing, such as the use of urine dipstick analysis, may offer unique opportunities to improve patient care, especially when combined with semi-automated reading devices. Placing point-of-care testing alongside laboratory test- ing offers the potential to detect ‘classic’ markers of chronic kidney disease such as albuminuria, as well as less commonly explored markers such as haematuria, which may have added significance in certain settings.